ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Improved structure preservation with neo-adjuvant platinum-based chemo in patients with resectable NPNSCC
Retifanlimab plus chemo shows PFS benefit in recurrent or metastatic squamous cell carcinoma of the anal canal
TNBC: Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS compared to neoadjuvant chemo alone
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Durable responses in aRCC, how do we optimise treatment?